Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390

Diabetes Care. 2023 May 1;46(5):e120. doi: 10.2337/dc23-0134.

Authors

Mark M Smits^{1

2

3}, Daniël H van Raalte^{1

2}

Affiliations

¹ 1Department of Endocrinology and Metabolism and Diabetes Center, Amsterdam UMC location Vrije Universiteit, Amsterdam, the Netherlands.
² 2Amsterdam Cardiovascular Sciences, Diabetes & Metabolism, Amsterdam, the Netherlands.
³ 3Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

PMID: 37185688
DOI: 10.2337/dc23-0134

No abstract available

Publication types

Letter
Comment

MeSH terms

Diabetes Mellitus* / drug therapy
Diabetes Mellitus* / epidemiology
Glucagon-Like Peptide-1 Receptor Agonists
Humans
Hypoglycemic Agents
Thyroid Neoplasms* / epidemiology

Substances

Hypoglycemic Agents
Glucagon-Like Peptide-1 Receptor Agonists